NICE guidance in development on docetaxel use in prostate cancer
23rd Dec 2005, 10:43 GMT
The NICE Appraisal Committee has developed preliminary recommendations on the use of docetaxel for the treatment of hormone-refractory metastatic prostate cancer.
NICE guidance in development on docetaxel use in prostate cancer related news:
- Prostate Cancer Screening Cuts Death Risk (HealthDay) — Yahoo! Health: Prostate Cancer News
- Prostate Cancer Treatment Causes Bone Loss (HealthDay) — Yahoo! Health: Prostate Cancer News
- Marital Status Affects Prostate Cancer Treatment Choices (HealthDay) — Yahoo! Health: Prostate Cancer News
- Prostate Surgery Safe for Older Men (HealthDay) — Yahoo! Health: Prostate Cancer News
- Gene Discovery Could Broaden Cancer Research (HealthDay) — Yahoo! Health: Prostate Cancer News
- 3-D Mapping Evaluates Prostate Cancer — NBC 17 - Health
- [Medical_Sciences] A cancer DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis — Proceedings of the National Academy of Sciences recent issues
- Counseling helps sex life after prostate cancer — KeralaNext: Health
- NICE Appraisal Of Hormonal Treatments For The Treatment Of Early Breast Cancer, Compared With Tamoxifen, UK — Medical News Today RSS/XML Feed
- Body backs Sanofi's Taxotere in prostate cancer — KeralaNext: Business
Latest news from OnMedica Latest News:
- Diagnosis by internet now popular and can work
- Draft NICE guidance on substance misuse available for consultation
- MDU advise on healthcare assitants giving flu vaccinations
- Drinking not recognised as mouth cancer cause
- More confusion over painkillers revealed
- New sexual health campaign for young adults
- NHS financial crisis is squeezing medical education
- World Diabetes Day is today
- NHS patients to choose hospitals through local libraries
- Patient hospital choice system needs improvement